SUNNYVALE, Calif.--(BUSINESS WIRE)--July 18, 2006--Adeza (NASDAQ:ADZA - News) today announced that its New Drug Application (NDA) for Gestiva(TM) will be reviewed by the Reproductive Health Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) on August 29, 2006. Gestiva, a long acting form of a naturally occurring progesterone, is the company's drug candidate to prevent preterm birth in women with a history of preterm delivery.
